video thumbnail

Merck’s Molnupiravir (EIDD-281) Effective Against SARS-COV-2

Duration: 29:11

Write A New Comment

0 Comments

Merck’s Molnupiravir (EIDD-281) Effective Against SARS-COV-2

Molnupiravir is a nucleoside analog. It has shown to be able to cause mutations accumulation and the RNA replication errors during the virus replication in vitro and in mouse models (in-vivo).

Let’s look at the following
What is Molnupiravir?
What is EIDD-281?
What is a nucleoside and a nucleotide?
How is positive mRNA is replicated to a negative sense RNA and back again during the viral replication?
How does EIDD-281 disrupt this process?
Why is it better performing than Remdesivir?
It’s therapeutic dose is non cytotoxic.
Concerns about its toxicity in humans.


References
https://stm.sciencemag.org/content/12/541/eabb5883
https://en.wikipedia.org/wiki/Molnupiravir
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848974/
https://en.wikipedia.org/wiki/Nucleoside
https://en.wikipedia.org/wiki/Nucleotide
https://www.reuters.com/article/us-health-coronavirus-merck-co/merck-says-study-shows-covid-19-drug-causes-quick-reduction-in-virus-idUSKBN2AY07U
https://clinicaltrials.gov/ct2/show/NCT04405739

 

Merck has a new drug molecule for SARS-COV-2. It is named Molnupiravir or EIDD-2801. We will discuss the following topics about this drug.

 

  1. Need for this anti-viral drug to be used with Remdesivir.
  2. History of the EIDD-2801.
  3. Trial for phase II and phase III.
  4. Route of administration.
  5. Drug properties.
  6. Mechanism of action.
  7. Results in mouse studies.
  8. Therapeutic index.

Following answers are created by ChatGPT. Occasionally the answer may be harmful, incorrect, false, misleading, incomplete, or limited in knowledge of world. Please contact your doctor for all healthcare decisions. Also, double check the answer provided by the AI below.

Please login to access this content.

Don't have an account?

Start Your Free trial

No credit card information needed.

Pharmacology

Related Videos